Exposure–response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane

被引：1
|
作者：
Chunze Li
Bei Wang
Shang-Chiung Chen
Russell Wada
Dan Lu
Xin Wang
Daniel Polhamus
Jonathan French
Shweta Vadhavkar
Alexander Strasak
Melanie Smitt
Amita Joshi
Meghna Samant
Angelica Quartino
Jin Jin
Sandhya Girish
机构：
[1] Genentech,Department of Clinical Pharmacology
[2] Inc.,undefined
[3] Certara Strategic Consulting,undefined
[4] Certara,undefined
[5] Stastical Modeling and Simulation,undefined
[6] Metrum Research Group,undefined
[7] Biostatistics,undefined
[8] F. Hoffmann-La Roche,undefined
[9] Clinical Sciences,undefined
[10] Genentech,undefined
[11] Inc.,undefined
[12] Biostatistics,undefined
[13] Genentech,undefined
[14] Inc.,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2017年 / 80卷
关键词：
Trastuzumab emtansine (T-DM1); Exposure–response relationship; Pharmacokinetics; Antibody–drug conjugate (ADC); Metastatic breast cancer; Human epidermal growth factor receptor 2 (HER2);
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1079 / 1090
页数：11
相关论文
共 50 条
  • [1] Exposure-response analyses of trastuzumab emtansine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane
    Li, Chunze
    Wang, Bei
    Chen, Shang-Chiung
    Wada, Russell
    Lu, Dan
    Wang, Xin
    Polhamus, Daniel
    French, Jonathan
    Vadhavkar, Shweta
    Strasak, Alexander
    Smitt, Melanie
    Joshi, Amita
    Samant, Meghna
    Quartino, Angelica
    Jin, Jin
    Girish, Sandhya
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1079 - 1090
  • [2] Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
    Verma, Sunil
    Miles, David
    Gianni, Luca
    Krop, Ian E.
    Welslau, Manfred
    Baselga, Jose
    Pegram, Mark
    Oh, Do-Youn
    Dieras, Veronique
    Guardino, Ellie
    Fang, Liang
    Lu, Michael W.
    Olsen, Steven
    Blackwell, Kim
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19): : 1783 - 1791
  • [3] Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
    Dhillon, Sohita
    DRUGS, 2014, 74 (06) : 675 - 686
  • [4] Trastuzumab Emtansine: A Review of Its Use in Patients with HER2-Positive Advanced Breast Cancer Previously Treated with Trastuzumab-Based Therapy
    Sohita Dhillon
    Drugs, 2014, 74 : 675 - 686
  • [5] Trastuzumab emtansine for HER2-positive breast cancer
    Venkatesan, Priya
    LANCET ONCOLOGY, 2016, 17 (12): : E528 - E528
  • [6] Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
    Chen, Shang-Chiung
    Kagedal, Matts
    Gao, Yuying
    Wang, Bei
    Harle-Yge, Marie-Laurence
    Girish, Sandhya
    Jin, Jin
    Li, Chunze
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 80 (06) : 1147 - 1159
  • [7] Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
    Shang-Chiung Chen
    Matts Kagedal
    Yuying Gao
    Bei Wang
    Marie-Laurence Harle-Yge
    Sandhya Girish
    Jin Jin
    Chunze Li
    Cancer Chemotherapy and Pharmacology, 2017, 80 : 1147 - 1159
  • [8] NICE guidance on trastuzumab emtansine for HER2-positive advanced breast cancer
    Elsada, Ahmed
    Doss, Sally
    Robertson, Janet
    Adam, E. Jane
    LANCET ONCOLOGY, 2016, 17 (02): : 143 - 144
  • [9] Trastuzumab emtansine in HER2-positive metastatic breast cancer
    Montemurro, Filippo
    LANCET ONCOLOGY, 2017, 18 (06): : 696 - 697
  • [10] Correction to: Population pharmacokinetics of trastuzumab emtansine in previously treated patients with HER2-positive advanced gastric cancer (AGC)
    Shang-Chiung Chen
    Matts Kagedal
    Yuying Gao
    Bei Wang
    Marie-Laurence Harle-Yge
    Sandhya Girish
    Jin Jin
    Chunze Li
    Cancer Chemotherapy and Pharmacology, 2018, 81 : 421 - 422
12345